DMF, DMSO, Ethanol, PBS (pH 7.2)
Bosutinib is a novel tyrosine kinase inhibitor. Bosutinib can overcome not only Bcr-Abl-dependent mechanisms of resistance, but also those that are Bcr-Abl-independent. It is used to treat patients with chronic myelogenous leukemia (CML) who demonstrate resistance to Imatinib or develop resistance during treatment.
Research or further manufacturing use only, not for food or drug use.